Bedrijfsoverzicht
Achieve Life Sciences, Inc. is a late-stage pharmaceutical entity dedicated to the development and commercialization of cytisinicline, a plant-based alkaloid designed to facilitate nicotine independence across the markets of Canada, the United States, and the United Kingdom. This specific therapeutic approach involves a compound that interacts directly with nicotine receptors within the brain, distinguishing the company's operational model within the broader healthcare landscape. The firm operates specifically within the healthcare sector and the biotechnology industry, positioning itself as a specialized player in the pharmaceutical pipeline rather than a diversified conglomerate. As of the latest available data, the company holds a market capitalization of $185.81M and employs a workforce of 28 individuals, indicating a lean organizational structure typical of biotech firms in the late-stage development phase. The current market cap of $185.81M, combined with the reported annual revenue figures being unavailable, suggests that the company's valuation is heavily influenced by its asset pipeline and potential future commercialization rather than current earnings generation, a common characteristic for biotechnology enterprises that have not yet achieved significant profitability or widespread sales revenue.
Financiële gezondheid
The company reported a net income of $-54,648,000 and an EBITDA of $-54,652,000 over the trailing twelve months, while annual revenue figures are not available in the current dataset. The substantial negative net income relative to the unavailable revenue data indicates a cost structure characterized by significant operational expenses, likely driven by research and development activities and commercialization efforts typical of late-stage pharmaceutical companies. Free cash flow stands at $-28,461,876, which signifies that the company is currently burning cash to fund its operations and product development, thereby limiting its immediate financial flexibility without external capital injections. The analysis of the three margin metrics reveals a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, all of which indicate that the company has not yet generated positive earnings before interest and taxes or realized net profits, reflecting the high-cost nature of bringing a new drug to market. On the balance sheet side, the company holds $36.40M in cash against $14.96M in debt, resulting in a debt-to-equity ratio of 69.50, which suggests a leveraged position where equity is less than the debt load, yet the substantial cash reserve provides a buffer against this leverage. The current ratio is reported at 4.39, a figure that indicates robust short-term liquidity, suggesting the company possesses ample current assets to cover its short-term obligations despite the negative earnings position. Furthermore, the return on equity is -257.7% and the return on assets is -85.3%, metrics that reveal that management has not yet achieved positive returns on the capital invested or the assets utilized, a standard but critical challenge for biotechnology firms in the pre-revenue or early commercialization stages.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E is reported at -3.36, implying that the market is pricing in future earnings that are not yet realized or that the company is currently unprofitable. The price-to-book ratio stands at 8.64, a metric that indicates the market is valuing the company at a significant premium over its net asset book value, a common scenario for biotech firms where the value of intellectual property and the potential of the cytisinicline pipeline exceeds the tangible assets recorded on the balance sheet. The price-to-sales ratio is also N/A, and the EV/EBITDA stands at -3.01, suggesting that traditional valuation multiples are less applicable and that the enterprise value is heavily dependent on projected cash flows rather than current operational profitability. The stock has traded within a 52-week range between a low of $1.95 and a high of $6.03, meaning the current price position fluctuates within this established volatility band, with the upper limit reflecting peak market sentiment during the period. The beta value is 1.96, which indicates that the stock's price volatility is nearly double that of the broader market, exposing investors to significantly higher risk and potential reward compared to the overall market index.
Growth & Income
The revenue growth year-over-year is listed as N/A, and earnings growth year-over-year is also N/A, preventing a direct comparison of the speed at which earnings are growing relative to revenue because the necessary historical data points are not available in the current facts. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the firm does not distribute earnings to shareholders but instead retains all available capital, including the cash reserves of $36.40M, to reinvest into research, development, and the commercialization of cytisinicline. The absence of a dividend payout ratio is sustainable given the negative net income of $-54,648,000, as distributing dividends would be financially unsustainable for a company with negative earnings and negative free cash flow of $-28,461,876. In summary, the overall growth and income profile for Achieve Life Sciences, Inc. is defined by a focus on capital preservation and reinvestment into the biotechnology pipeline rather than generating current income through dividends or positive earnings growth, a strategic posture typical of late-stage pharmaceutical companies awaiting regulatory approval and market entry.